ROS-Responsive Nanosystem Targeted Co-Delivery YC-1 and Regorafenib to Alleviate Hypoxia Enhancing Hepatocellular Carcinoma Therapy
The successfully developed RYP-RGD NPs offer a novel strategy for HCC treatment. They enhance drug targeting, synergistically boost the therapeutic effect, and maintain biosafety, showing great potential for clinical translation.
Authors
- Ruopeng Liang
- Binghua Sun
- Liming Song
- Yuling Sun (ORCID: https://orcid.org/0000-0001-5289-4673)
- Yupeng Shi (ORCID: https://orcid.org/0000-0002-7679-5386)
- Senfeng Zhao (ORCID: https://orcid.org/0000-0002-8038-0167)
- Weijie Wang (ORCID: https://orcid.org/0000-0002-5717-3602)
- Yin Liu (ORCID: https://orcid.org/0009-0004-4044-958X)
- Rongtao Zhu (ORCID: https://orcid.org/0000-0003-3655-9458)
- Yunpeng Zhai (ORCID: https://orcid.org/0000-0002-3344-4543)
- Yahui Wu
- Jiahui Cao
- Yaning Xia
- Zhipu Liu
Institutions
- Zhengzhou University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-06-30
- DOI
- https://doi.org/10.2147/ijn.s518120
- Citations
- 2
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 1.35